-
U.S. court rules in favour of Biotec Pharmacon ASA
Biotec Pharmacon reports that Biothera has been denied permission to file a motion to reconsider the U.S District Court Order of 28 January, 2009, which largely ruled in Biotec Pharmacon's favour in a patent infringement suit. The Court's decision confirms that all of Biothera's claims under 12 of 14 U.S. patents at issue have been dismissed from the case without even requiring a trial.
>> Read more13.02.09 -
Photocure receives a grant of NOK 4.3 mill
Photocure ASA has been rewarded NOK 4.3 mill (~€ 0.5 mill) over 3 years from the BIA program of the Norwegian Research Counsel (NFR). The BIA program supports highly innovative projects that create value to both the company and society.
>> Read more13.02.09 -
Algeta to enroll US patients in new trial
Algeta ASA, the cancer therapeutics company, announces that it is to enroll US patients into its ALSYMPCA phase III trial evaluating Alpharadin as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).
>> Read more04.02.09 -
Favourable ruling for Biotec Pharmacon
A decision by the U.S district court judge in Minnesota largely rules in Biotec Pharmacon's favour in the patent infringement suit brought by Biopolymer Engineering.
>> Read more04.02.09 -
Algeta completes comprehensive clinical program
Algeta ASA has now completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC). The program provides strong evidence that Alpharadin can prolong patient survival times, improve quality of life and offers a placebo-like safety profile.
>> Read more15.01.09 -
- Forskningsrådets forslag trenger justeringer
Norsk Biotekforum (NBA) har kritiske kommentarer til Norges forskningsråds nye forslag til fordeling av rettigheter til resultater fra prosjekter. NBA beklager blant annet at bioteknologibedriftene ikke har vært med i utvalget som utarbeidet forslaget, til tross for at bransjen er sterkt berørt av Forskningsrådets politikk på området. Organisasjonen ber nå om å bli invitert til å delta i arbeidet med malene for nye konsortieavtaler. Se for øvrig foredragene fra Brennpunkt-møtet 5. februar.>> Read more08.01.09 -
Bionor Immuno wins price for Innovation
Bionor Immuno has been awarded the Norwegian Research Council’s prestigious "Most Innovative Company of the Year" award. The award is determined by a panel of 3,500 business leaders.
>> Read more06.12.08 -
Strong Growth in Clinical Trials in Norway
The Norwegian Bioindustry Association has carried through a new survey of the Norwegian pharmaceutical pipeline. This year 20 projects are in late pre-clinical trials (15 in 2007) and 35 projects are in clinical trials (31 in 2007).
>> Read more19.11.08 -
Positive interim results from testing of Cevira
Photocure ASA has presented positive interim data from the clinical feasibility study of the company's photodynamic therapy Cevira.
>> Read more17.11.08 -
Helseforetakene og næringslivet bør styrke forskningssamarbeidet
Norge har et helsevesen som internasjonalt er langt fremme, og hvor mulighetene for å kunne skape nye produkter for et internasjonalt marked bør være store. Det er imidlertid en svakhet at helseforetakenes resultatbaserte tilskudd til forskning ikke har et kriterium for anvendt forskning, skriver Norsk Biotekforum i et brev til Helse- og omsorgsdepartementet. >> Read more07.10.08
Norwegian Bioindustry Association
Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98